Skip to main content

Peer Review reports

From: FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

Original Submission
15 Feb 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
Resubmission - Version 7
Submitted Manuscript version 7
Author responded Author comments
Resubmission - Version 8
Submitted Manuscript version 8
Resubmission - Version 9
Submitted Manuscript version 9
Author responded Author comments
Resubmission - Version 10
Submitted Manuscript version 10
Author responded Author comments
Resubmission - Version 11
Submitted Manuscript version 11
Author responded Author comments
Resubmission - Version 12
Submitted Manuscript version 12
Author responded Author comments
Resubmission - Version 13
Submitted Manuscript version 13
Author responded Author comments
Resubmission - Version 14
Submitted Manuscript version 14
Publishing
28 Jan 2016 Editorially accepted
8 Feb 2016 Article published 10.1186/s12885-016-2097-4

You can find further information about peer review here.

Back to article page